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Abstract
In this observational study we examined the impact of disease-modifying antirheumatic drugs (DMARDS) on the 
disease activity as well as the values of acute phase reactants and the apolipoprotein A1 (Apo A1) in patients with active 
rheumatoid arthritis (RA). Eighty patients with active RA and newly discovered RA patients who meet the American 
Rheumatology Association (ARA) 1987 revised criteria were treated with disease modifying anti-rheumatic drugs – 
DMARDs according to the standard protocol of everyday clinical practice. At 6 and 12 months of treatment the  patients 
achieved a signifi cant decrease in the disease activity score 28 (DAS28), C-reactive protein (CRP), and erythrocyte 
sedimentation rate (ESR) values. On the other hand, the levels of Apo A-1, which were low at baseline, were signifi -
cantly higher. In conclusion, the use of DMARDs in patients with RA reduced disease activity and infl ammation, but 
also had a benefi cial eff ect in increasing the levels of atheroprotective Apo A-1 lipoprotein, which can reduce CV risks 
in these patients.
Keywords: Arthritis, rheumatoid – drug therapy; Antirheumatic agents – pharmacology, therapeutic use; Apo-
lipoprotein A-1 – blood; Blood sedimentation; C-reactive protein – analysis; Severity of illness index; Atherosclerosis 
– metabolism, prevention and control
Sažetak
U ovom opservacijskom radu istražili smo utjecaj antireumatskih lijekova koji mijenjaju tijek bolesti (BMARL) na: 
aktivnost bolesti, vrijednosti reaktanata akutne faze i apolipoproteina A-1 (Apo A-1) u bolesnika s aktivnim  reumatoidnim 
artritisom (RA). Osamdeset pacijenata s aktivnim i novootkrivenim RA, u skladu s revidiranim klasi fi kacijskim kriteri-
jima Američkoga reumatološkog udruženja (ARA) iz 1987. godine, liječeno je lijekovima koji mijenjaju tijek upalne 
reumatske bolesti – BMARL-ima, u skladu sa standardnim protokolom liječenja u svakodnevnoj praksi. Nakon 6 i 12 
mjeseci liječenja pacijenti su postigli značajno smanjenje vrijednosti DAS28 (disease activity  score), CRP-a (C-reaktivni 
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povisile. Zaključno, primjena BMARL-a u bolesnika s RA smanjila je aktivnost bolesti i  upalu, ali je imala pozitivne 
učinke u smislu povišenja razine ateroprotektivnog Apo A-1, što može sniziti kardiovaskularne rizike.
Ključne riječi: Reumatoidni artritis – farmakoterapija; Antireumatici – farmakologija, terapijska primjena; 
Apolipoprotein A-1 – u krvi; Sedimentacija krvi; C-reaktivni protein – analiza; Indeks težine bolesti; Ateroskleroza – 
metabolizam, prevencija
Another group of researchers focused on the func-
tion of HDL-C. Normal HDL-C shows its antiathero-
genic role by protecting LDL-C from oxidation and 
inhibiting the expression of adhesion molecules and 
their role in the reverse transport of cholesterol. Th ese 
antioxidant eff ects are largely dependent on the HDL-C 
content of apolipoprotein A-1 (Apo A-1) and the en-
zyme paraoxonase (PON1) (15). During acute-phase 
responses, HDL loses this antioxidant capacity and can 
even promote an increased oxidation of LDL, thus 
 becoming pro-infl ammatory. According to some au-
thors, pro infl ammatory HDL-C was detected more 
oft en in patients with RA than in controls. Th erefore, 
pro infl ammatory HDL-C can be a novel biomarker for 
the increased atherosclerotic risk in RA (16–20). Apo 
A-1-containing particles mediate the reverse choles-
terol transport, returning excess cholesterol from pe-
ripheral tissues to the liver, the only organ capable of 
excreting it in signifi cant quantities (in bile). Also, Apo 
A-1 is a major protein of HDL-C, and its main function 
is to act as a structural protein, to mediate the transfer 
of cholesterol from cell surfaces to lipoprotein parti-
cles, and to activate the enzyme responsible for choles-
terol esterifi cation in the circulation (21).
Th e aim of this study was to examine Apo A-1 levels 
in newly diagnosed patients with active RA and conven-
tional synthetic disease-modifying drug (csDMARD)-
-naïve RA patients, as well as the impact of treatment 
with csDMARDs on acute phase reactants and Apo 
A-1 lipoproteins at 6 and 12 months of treatment.
Material and methods
A group of 80 patients with active RA and DMARD-
-naïve RA patients were enrolled in this study. Th ese 
patients were treated with csDMARDs and followed 
up for 12 months. Th e study was conducted at the 
Rheumatology Clinic of the Clinical Center Skopje and 
the Clinical Center in Tetovo, Republic of Macedonia. 
All the patients with RA met the ARA 1987 revised 
classifi cation criteria. Exclusion criteria were condi-
tions that may directly or indirectly aff ect the status of 
lipids, such as: Cushing syndrome, diabetes mellitus, 
acute infections, advanced diseases of liver, kidney, 
thyroid, CVD and associated conditions (stroke, myo-
cardial infarction), cancer, treatment with beta block-
ers, vitamin E, hypolipidemic drugs, oral contracep-
tives, pregnancy, BMI over 30 kg/m2, and vegetarian/
vegan diet (22, 23).
Introduction
Rheumatoid arthritis (RA) is the most common in-
fl ammatory chronic arthritis. It is a symmetric polyar-
thritis associated with signifi cant structural damage 
and functional impairment. Th e main goals of treat-
ment in RA are: controlling the signs and symptoms of 
the disease, preventing further damage of joints, and 
improving functional ability. Studies conducted many 
years back have shown that patients with RA die at a 
younger age compared to the general population (1–3). 
In general, the most common cause of death is cardio-
vascular disease (CVD), and patients with RA are at a 
2–5 times higher risk to develop a CVD, which in turn 
leads to a 5–10 years shorter lifespan than that of the 
general population (4, 5).
Various studies have confi rmed that endothelial dys-
function and dyslipidemia are present in patients with 
RA. Immune deregulations with systemic infl amma-
tion are integral parts of the development of athero-
genesis, and the majority of cardiovascular (CV) deaths 
in patients with RA result from accelerated atheroscle-
rosis (3, 6–8). Th ere is a signifi cant association between 
the immunological and pathological processes occur-
ring in the synovium and atheromatic lesions of blood 
vessel walls. Higher levels of rheumatoid factor (RF), 
anti-cyclic citrullinated peptide antibodies (anti-CCP), 
markers of systemic infl ammation like erythrocyte 
sedimentation rate (ESR), C-reactive protein (CRP), 
or some pro-infl ammatory cytokines (tumor necrosis 
factor a – TNF-a; interleukin-6, IL-6), as well as a high-
er number of infl amed joints, considerable dysfunc-
tion at disease onset, and the presence of extra-arti-
cular changes are closely related to CV changes that 
occur in patients with RA (6–10).
In general, the lipid profi le of patients with active 
and newly discovered RA is characterized by a decrease 
in serum levels of high density lipoproteins (HDL), to-
tal cholesterol (TC), and low-density lipoproteins 
(LDL); thus, according to some authors, low TC and 
LDL levels are associated with an increased CV risk 
(11–14). It is important to note that the reduction of 
HDL levels results in increasing the ratio of TC/HDL, 
an atherogenic index, which in turn is a very important 
prognostic marker for CVD. Th e levels of TC and HDL 
cholesterol (HDL-C) in RA are inversely correlated 
with disease activity, which confi rms the role of in-
fl ammation in the atherogenic profi le of these patients 
(11, 13).
Reumatizam 2016;63(2):9–14 11
Ismaili H. et al. Eff ect of treatment on apolipoprotein A-1 and disease activity in RA Professional paper
Th e distribution of treatment with DMARDs ac-
cording to drugs was as follows: 46 patients were treat-
ed with methotrexate (average dose 15 mg OW), 23 
patients with hydroxychloroquine (300 mg OD), 9 pa-
tients with sulfasalazine (2–3 g/day), 1 patient with 
gold salts (25–50 mg OW), and 1 patient with azathio-
prine (150 mg TD). Th e patients who did not respond 
to the therapy according to the American College of 
Rheumatology (ACR) 20 criteria (n=7) were excluded 
from the follow up.
Th e laboratory tests were performed at the Institute 
of Biochemistry in Skopje at baseline as well as at 6 and 
12 months during the treatment with DMARDs. Th e 
serum levels of Apo A-1 were determined using the 
 radial immunodiff usion method. Th e ESR was deter-
mined by the Westergren method and CRP by immu-
nofl uorometric methods. Blood samples were taken in 
the morning, aft er at least 12 hours of fasting, as well as 
aft er consumption of greasy food the day before draw-
ing blood samples. Th e rheumatoid factor test was per-
formed using the latex method.
Immediately before the treatment, as well as at 6 and 
12 months, several parameters of disease activity and 
functional ability were obtained, too: Tender Joint 
Count (TJC), Swollen Joint Count (SJC), Global pa-
tient’s assessment (on horizontal VAS), and Global 
physician’s assessment (on horizontal VAS). Th e physi-
cal examination was done by experienced rheumatolo-
gists (HI, NK). A structured questionnaire was used to 
obtain the data.
Th e main characteristics of the patients are present-
ed in Table 1.
the parameters was analyzed using Pearson’s correla-
tion coeffi  cient. Signifi cance was set up at p <0.05.
Results
DAS28 scores aft er 6 months of treatment were 
 signifi cantly lower that at baseline (p<0.01), and the 
diff erence was even more pronounced at 12 months 
in comparison to baseline, as well as in comparison to 
the results obtained at 6 months (p<0.001 for both) 
(Figure 1).
Table 1. Patient characteristics (n=80)




Tender Joint Count (28) 7.8±7.1
Swollen Joint Count (28) 5.2±3.7
Global patient’s assessment of the disease (on VAS) 7.0±2.1
Global physician’s assessment of the disease (on VAS) 4.5±2.3
ESR (mm/h) 45.4±30.3
CRP (mg/L) 41.4. ±29.4
RF positive/negative 67/13
Legend: BMI: body mass index, ESR: erythrocyte sedimentation 
rate, CRP: C-reactive protein
Statistical analysis was performed using Statistica 
soft ware, ver 7.1. Due to the distribution which was 
not normal (according to Kolmogorov-Smirnov test), 
the variable diff erences were tested using non-para-
metric tests (Wilcoxon Matched Pair Test or Friedman 
ANOVA test – Chi Square). Th e correlation between 
Figure 1. Disease activity score 28 (DAS28) at baseline, 
at 6, and at 12 months during the treatment
Slika 1. Indeks aktivnosti bolesti (DAS28) na početku 
te nakon 6 i 12 mjeseci liječenja
Table 2. ESR and CRP levels at baseline, at 6 months, 
and at 12 months
Tablica 2. Razina SE i CRP-a na početku te nakon 6 




Ranks Mean Std. Dev
ESR at baseline 2.53 182.50 40.78 28.07
ESR at 6 months 1.99 143.50 29.06 22.29
ESR at 12 months 1.47 106.00 24.89 22.15
CRP at baseline 2.44 175.50 21.69 15.98
CRP at 6 months 2.08 150.50 20.51 36.19
CRP at 12 months 1.48 106.50 12.31 11.95
As for ESR and CRP, there was a signifi cant consecu-
tive decrease from baseline, both at 6 and at 12 months 
(for both variables, between each of time-points; Fried-
man ANOVA; p <0.001) (Table 2).
Table 3. Levels of Apolipoprotein A-1 (Apo A-1) at baseline, 
at 6 months, and at 12 months
Tablica 3. Razina apolipoproteina A-1 (Apo A-1) na početku 




Rank Mean St. Dev.
Apo A-1 at baseline 1.63 117.00 1.91 0.35
Apo A-1 at 6 months 1.83 132.00 1.96 0.43
Apo A-1 at 12 months 2.54 183.00 2.08 0.37
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Table 3 shows the results of testing for Apo A-1 at 
baseline, at 6 months, and at 12 months. Th ere was a 
signifi cant diff erence between Apo A-1 levels in the 
specifi ed period: the levels decreased during the thera-
py (Friedman ANOVA; p <0.001).
Comparing the results of ESR, CRP, and Apo A-1 at 
baseline, at 6 months, and at 12 months, we found a 
moderately weak signifi cant negative correlation only 
in relation to the values of ESR and Apo A1 at 12 
months (r = –0.28; p<0.05). In other words, the eleva-
tion of ESR by 1mm/hour was accompanied by a de-
crease of Apo A1 values by 0.005 g/l (Figure 2). As for 
the relationship of the other variables, we found a 
moderately poor and weak insignifi cant correlation 
(p>0.05) (data not shown).
Discussion
Data support the view that chronic infl ammation af-
fects the endothelium, and that, in association with 
dyslipidemia, it may be the mechanism that at least 
partly explains the increased mortality and morbidity 
occurring in patients with RA. Our goal was to deter-
mine the values of Apo A-1 lipoproteins in patients 
with active RA and DMARD-naïve RA patients before 
treatment and aft er 6 and 12 months of treatment with 
csDMARDs. Th e patients with active RA had low lev-
els of Apo A-1 before the treatment, while aft er 6 and 
12 months of treatment with csDMARDs the Ap A-1 
levels signifi cantly increased. On the other hand, the 
values of acute phase reactants (ESR and CRP) were 
lower aft er 6 months and one year of treatment. Th is 
suggests that increasing levels of Apo A-1 lipoproteins 
were accompanied by a decrease of infl ammation at 
the end of the study. In other words, the results tell us 
that the infl ammation in RA in some way induces the 
proatherogenic lipid profi le. Conventional therapy 
with DMARDs has a positive eff ect on Apo A-1 values 
and atherogenic index Apo B/Apo A1. Th is is in accor-
dance with other fi ndings supporting the thesis that 
treatment with DMARDs has an impact on the mecha-
nisms that aff ect cardiovascular morbidity and mortal-
ity in these patients (7, 8, 11, 21, 23).
A broad body of evidence indicates that infl amma-
tion contributes to the pathogenesis of atherosclerosis 
and CVD in the general population. Epidemiological 
studies suggest that a number of pro-infl ammatory 
factors, such as CRP, ESR, fi brinogen, and some cyto-
kines are involved in the mediation of this process. 
Th ey not only promote endothelial dysfunction and 
structural vessel abnormalities, but also induce other 
cardiovascular risk factors, such as changes in lipid lev-
els, insulin resistance, and oxidative stress. Th ey are 
increased in RA patients and some studies have dem-
onstrated a signifi cant association between their levels, 
ESR in particular, and the risk of CVD (11, 18, 24).
Th e underlying cause of atherosclerosis are autoim-
mune infl ammatory disorders, in which lipoprotein 
metabolism alterations are associated with the activa-
tion of the immune system, with consequent prolifera-
tion of smooth muscle cells, narrowing of the arteries, 
and formation of atheroma (25). Th erefore it is plausi-
ble to infer that atherosclerosis and RA share common 
pathogenetic mechanisms. For instance, CRP, which is 
increased in active RA, may contribute to atherosclero-
sis because it stimulates macrophages to produce tissue 
factor, a procoagulant found in atherosclerotic plaques. 
On the other hand, the presence of CRP in atheroma-
tous lesions suggests the cause-and-eff ect relationship 
between this acute phase reactant and coronary artery 
events (11, 13, 24, 26, 28).
When lipid profi les were investigated in patients 
with RA, some of them showed lower values of HDL-C 
and TC, and increased values of lipoprotein-A (Lp-A), 
with increased proportions of TC/HDL, LDL/HDL, 
and Apo B/Apo A-1 in patients with active RA and 
DMARD-naïve RA patients, compared to the general 
population (16, 20, 31). Lipids may have paradoxical 
associations with the risk of CVD in RA, where lower 
TC and LDL levels are associated with an increased CV 
risk, called the “lipid paradox”. Also, there are studies 
that show a decline across the lipid fraction in the acute 
phase of the illness. Such diff erences that arise in dif-
ferent diseases can be explained by insuffi  cient sample 
size, type of study (prospective, cross-sectional, or ob-
servational), as well as diff erences in the disease type 
(early or established) or disease activity (14, 16, 24, 25).
One of the fi rst controlled studies reporting on apo-
lipoprotein levels in RA was performed in 42 untreated 
patients (mean disease duration 27 months) and 42 
age- and sex-matched controls. Th e authors presented 
the 12-month changes and found that CRP levels cor-
related signifi cantly with the change in HDL-C levels 
Figure 2. Correlation of ESR and Apo A-1 levels at 12 months
Slika 2. Korelacija vrijednosti SE i Apo A-1 nakon 12 mjeseci 
liječenja
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(r=–0.38, p<0.001) and Apo A-1 levels (r=–0.29, 
p<0.01). Th e mean HDL-C levels increased by 21% 
(p<0.001), and the mean Apo A-1 levels increased by 
23% (p<0.001) aft er treatment with DMARDs. Studies 
also mention that the change of protective Apo A-1 
showed a strong negative correlation with the changes 
in CRP levels (26).
In their study, Taysi et al. presented signifi cantly 
higher values of Lp-A in the sera of RA patients com-
pared to those of the control group (p <0.01), while 
Apo A-1 levels were signifi cantly lower in patients with 
RA (p < 0.01). ESR and CRP were positively correlated 
with the levels of Lp-A in RA patients, and negatively 
correlated with HDL-C and Apo A-1. Th e authors also 
emphasized that RA patients with such lipid levels 
were at higher risk for developing CVD and athero-
sclerosis compared to controls (27).
Van Halm et al. support the observations that pa-
tients with RA have an atherogenic lipid profi le even 
10 years before the clinical onset of RA, which itself 
may explain the increase of cardiovascular risk in pa-
tients with RA. Th e study was conducted on 79 pa-
tients, blood donors who later developed RA. Th ese 
patients had low levels of HDL-C and high levels of 
TC, triglyceride (TG), and apolipoproteins B (Apo B) 
compared with controls, even 10 years before the dis-
ease appeared. Th is suggests that lipid changes are as-
sociated with, and in some way may be a promotive 
factor for, a higher susceptibility to RA; perhaps these 
patients are genetically predisposed for dyslipidemia, 
or the transcriptions of these genes are altered by the 
presence of infl ammation (28).
A recent research has shown that systemic infl am-
mation plays a pivotal role in the development of ath-
erosclerosis, and thus may explain the increased CV 
risk in RA patients. Also, this study confi rmed that in-
fl ammation leads to pro-atherogenic changes of the li-
poprotein metabolism, and an increased disease activ-
ity is associated with lower TC levels, as well as even 
more depressed HDL-C levels and lowered Apo A1 
levels (25).
Treatment with csDMARDs has benefi cial eff ects on 
the lipid profi le in RA, and it is tempting to assume 
that the favorable eff ect of these drugs on the CV mor-
bidity and mortality in RA might be partially mediated 
by this mechanism (30).
Management of dyslipidemia should be considered 
as part of the cardiovascular risk management in pa-
tients with RA. It is clear that good control of the dis-
ease has a positive eff ect on the lipid profi le, especially 
in increasing the anti-infl ammatory and atheroprotec-
tive Apo A-1 and HDL-C levels. An adequate treat-
ment of traditional, but also nontraditional, CV risk 
factors is absolutely necessary in these patients; this is 
supported by epidemiological studies in the fi eld, with 
more precise and comprehensive guidelines address-
ing this issue (29, 30–32).
Th e strength of our study is the coherent cohort of 
newly diagnosed patients with RA and the fact that the 
evaluation was done at the designated times, as well as 
the fact that the laboratory measurements were per-
formed using reliable methods. Th e obvious limitation 
is the design of the study with no control group, and 
the diff erences in treatment regimens during the study.
In conclusion, the results of our observational study 
indicate that patients with active RA and DMARD-
naïve RA patients have high levels of acute phase reac-
tants (ESR and CRP) and low levels of atheroprotective 
Apo A-1. Treatment of these patients with csDMARD-
s resulted in lower levels of disease activity paremeters 
and the increase of Apo A-1. Th erefore, apart from 
their benefi cial eff ects on disease activity, these drugs 
have positive eff ects in reducing the CV risk.
Disclosure: Th e authors declare no confl ict of inte-
rest.
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